Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
medroxyprogesterone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | DEPO-PROVERA® |
| Name | Type | Description |
|---|---|---|
| medroxyprogesterone acetate | DRUG | IM Injection |
Inclusion Criteria * Screening Demographics: All volunteers selected for this study will be healthy postmenopausal women 45 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Women - 1983 Metropolitan Height and ...
Medroxyprogesterone is a small molecule drug being investigated for use in healthy postmenopausal women. It is currently in Phase 1 clinical development, with a completed trial evaluating a 150 mg/1 mL injection. The drug is being developed by Teva Pharmaceutical Industries Limited.
Teva Pharmaceutical Industries Limited (TEVA) is developing medroxyprogesterone. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy postmenopausal women.
Medroxyprogesterone is in Phase 1 clinical development. One Phase 1 trial has been completed, which enrolled 124 healthy postmenopausal women in Germany. The drug is investigational and has not been approved by regulatory authorities.
Medroxyprogesterone has one completed clinical trial, NCT00830414, titled "Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women." This Phase 1 study enrolled 124 healthy female participants aged 45 years and older in Germany.
Medroxyprogesterone is the active ingredient in medroxyprogesterone acetate, which is the form used in the clinical trial. The study evaluated a 150 mg/1 mL injection of medroxyprogesterone acetate in healthy postmenopausal women.